Warfarin Dose Adjustment for INR 1.2
For a patient on warfarin 5 mg daily with an INR of 1.2 (assuming a target range of 2.0-3.0), give 10 mg today (double the usual dose) and increase the weekly maintenance dose by 5-10%, then recheck INR in 5-7 days. 1
Immediate Management
Based on the 2024 Italian FCSA guidelines, an INR <1.5 falls into the most subtherapeutic category and requires aggressive correction 1:
- Day 1 (today): Give a loading dose of twice the usual daily dose = 10 mg
- Ongoing: Increase the weekly maintenance dose by 5-10%
- Current weekly dose: 35 mg
- New weekly dose: 36.75-38.5 mg (round to practical dosing)
- This translates to approximately 5.25-5.5 mg daily
- Next INR check: 5-7 days 1
Bridging Anticoagulation Consideration
Consider adding LMWH bridging therapy depending on the patient's thrombotic risk 1:
- High thrombotic risk (mechanical heart valve, recent VTE, acute stroke): Full therapeutic-dose LMWH
- Moderate thrombotic risk: Intermediate-dose LMWH (50% of therapeutic dose)
- Low thrombotic risk: No bridging needed
The decision to bridge should be based on the indication for anticoagulation and individual patient factors. For patients with severe renal impairment (CrCl <30 mL/min), use unfractionated heparin instead 1.
Important Caveats
Before adjusting the dose, investigate and correct potential causes of subtherapeutic INR 1:
- Medication non-adherence - most common cause
- Drug interactions - new medications that induce warfarin metabolism
- Dietary changes - increased vitamin K intake
- Malabsorption - diarrhea, vomiting
- Dosing errors - verify patient is taking correct dose
If a clear reversible cause is identified (e.g., missed doses), you may opt for a more conservative approach with closer monitoring rather than a permanent dose increase.
Practical Dosing Strategy
Given that the patient is currently on 5 mg daily (35 mg weekly), a 5-10% increase means:
- Option 1: 5 mg six days per week, 7.5 mg one day per week (37.5 mg weekly)
- Option 2: Alternate 5 mg and 6 mg (approximately 38.5 mg weekly)
The 2024 FCSA guidelines note that for patients on very low weekly doses (≤6.25 mg/week), consider simple redistribution rather than dose increases 1. However, at 35 mg weekly, this patient is well above that threshold and requires a true dose increase.
Follow-up Monitoring
After the dose adjustment 1:
- Recheck INR in 5-7 days
- If INR remains <1.5, repeat the loading dose and increase weekly dose by another 5-10%
- Once INR reaches therapeutic range (2.0-3.0), continue weekly monitoring until stable for 2-3 consecutive measurements
- Then extend to every 2-4 weeks if consistently therapeutic
The FDA label supports initial dose adjustments based on INR response, with flexibility in dosing to achieve therapeutic range 2. Most patients are maintained on 2-10 mg daily, though individual requirements vary widely 2.